Literature DB >> 27613090

Identification of miR-125b targets involved in acute promyelocytic leukemia cell proliferation.

Yikai Zhang1, Chengwu Zeng2, Shuai Lu3, Tianyu Qin4, Lijian Yang4, Shaohua Chen4, Jie Chen5, Yangqiu Li6.   

Abstract

Acute promyelocytic leukemia (APL) is characterized by the presence of the PML-RARα fusion protein. We have previously found that PML-RARα-regulated miR-125b is highly expressed in APL; however, the characteristics of the regulatory effects and mechanisms of miR-125b involved in APL proliferation have yet to be clarified. In this study, we demonstrate that miR-125b promotes the proliferation of APL cells with the involvement of the PI3K/Akt and MAPK signaling pathways. Furthermore, we identified BTG2, MAP3K11, RPS6KA1 and PRDM1 as putative targets of miR-125b, which we verified using luciferase reporter constructs. Moreover, we demonstrate that the expression of miR-125b targets is downregulated in leukemic cells in patients with APL. Thus, our results provide evidence that miR-125b can modulate multiple oncogenic cell proliferation pathways and may be a novel therapeutic target for APL.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3′-untranslated regions; Acute promyelocytic leukemia; MicroRNAs; PML-RARα; Proliferation; Small non-coding RNAs

Mesh:

Substances:

Year:  2016        PMID: 27613090     DOI: 10.1016/j.bbrc.2016.09.020

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Blue light-induced apoptosis of human promyelocytic leukemia cells via the mitochondrial-mediated signaling pathway.

Authors:  Jianjian Zhuang; Yange Liu; Qingxia Yuan; Junsong Liu; Yan Liu; Hongdong Li; Di Wang
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

Review 2.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.